Phasebio Pharmaceuticals Inc., of Malvern, Pa., gained FDA orphan status for Vasomera (PB1046) injection for the treatment of cardiomyopathy associated with dystrophinopathies, including Duchenne muscular dystrophy, Becker muscular dystrophy and X-linked dilated cardiomyopathy. The company plans to initiate a phase IIa study of PB1046 in the first quarter of 2016.